mRNA vaccine development for cholangiocarcinoma: a precise pipeline

被引：7
|
作者：
Tang, Tian-Yu [1 ,2 ,3 ,4 ,5 ]
Huang, Xing [1 ,2 ,3 ,4 ,5 ]
Zhang, Gang [1 ,2 ,3 ,4 ,5 ]
Lu, Ming-Hao [1 ,2 ,3 ,4 ,5 ]
Liang, Ting-Bo [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Zhejiang Prov Key Lab Pancreat Dis, Sch Med, Hangzhou 310009, Peoples R China
[3] Zhejiang Clin Res Ctr Hepatobiliary & Pancreat Di, Hangzhou 310003, Zhejiang, Peoples R China
[4] Innovat Ctr Study Pancreat Dis Zhejiang Prov, Hangzhou 310009, Peoples R China
[5] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China
来源：
MILITARY MEDICAL RESEARCH | 2022年 / 9卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Cholangiocarcinoma (CHOL); mRNA vaccine; Tumor antigen; Immune subtype; Immune microenvironment; METASTATIC CHOLANGIOCARCINOMA; IMMUNE-RESPONSES; STRANDED-RNA; WEB SERVER; CANCER; CHEMOTHERAPY; RECOGNITION; MULTICENTER; GEMCITABINE; PEPTIDE;
D O I：
10.1186/s40779-022-00399-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.
引用
收藏
页数：6
相关论文
共 50 条
  • [41] New glioma vaccine in pipeline
    Burton, A
    LANCET ONCOLOGY, 2002, 3 (06): : 327 - 327
  • [42] A rational vaccine pipeline for tuberculosis
    Brennan, M. J.
    Stone, M. R.
    Evans, T.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (12) : 1566 - 1573
  • [43] Update on TB Vaccine Pipeline
    Martin, Carlos
    Aguilo, Nacho
    Marinova, Dessislava
    Gonzalo-Asensio, Jesus
    APPLIED SCIENCES-BASEL, 2020, 10 (07):
  • [44] Vaccine pipeline speeds up
    不详
    CHEMISTRY WORLD, 2006, 3 (02): : 10 - 10
  • [45] Vaccine adjuvants: is the pipeline clogged?
    Leitner, Wolfgang W.
    IMMUNOTHERAPY, 2012, 4 (06) : 565 - 567
  • [46] The 2016 Vaccine Development Pipeline: A special issue from the World Health Organization Product Development for Vaccine Advisory Committee (PDVAC) Preface
    Giersing, Birgitte K.
    Modjarrad, Kayvon
    Kaslow, David C.
    Okwo-Bele, Jean-Marie
    Moorthy, Vasee S.
    VACCINE, 2016, 34 (26) : 2863 - 2864
  • [47] Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma
    Frey, Alexander
    Perry, Curtis
    Olino, Kelly
    Ishizuka, Jeffrey Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development
    Ye, Liguo
    Wang, Long
    Yang, Ji'an
    Hu, Ping
    Zhang, Chunyu
    Tong, Shi'ao
    Liu, Zhennan
    Tian, Daofeng
    FRONTIERS IN GENETICS, 2021, 12
  • [49] Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development
    Chen, Zhuohui
    Wang, Xiang
    Yan, Zhouyi
    Zhang, Mengqi
    CANCER MEDICINE, 2022, 11 (13): : 2711 - 2726
  • [50] Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development
    Jiantao Fu
    Feng Chen
    Yuanji Lin
    Jin Gao
    Anna Chen
    Jin Yang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 4047 - 4061
12345